In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.

They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, focusing on practice-changing trials and innovative strategies that could shape future treatment landscapes.

Studies discussed include:

  • OptimUM-02 phase 2/3 trial for metastatic uveal melanoma
  • ADAM phase 3 trial for MCC
  • 5yr update of the phase 2 Keynote 942 trial (adjuvant melanoma)
  • Pilot neoadjuvant studies (NeoReNi, NeoINR)
  • Time of day of infusion and immunotherapy efficacy


Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör Melanoma Matters Pod. Innehållet i podden är skapat av Melanoma Matters Pod och inte av, eller tillsammans med, Poddtoppen.